Edition:
United States

Neurocrine Biosciences Inc (NBIX.O)

NBIX.O on Nasdaq

58.90USD
25 Sep 2017
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$58.90
Open
$58.72
Day's High
$59.80
Day's Low
$58.40
Volume
1,100,729
Avg. Vol
1,018,439
52-wk High
$60.00
52-wk Low
$37.35

Latest Key Developments (Source: Significant Developments)

Neurocrine Bio's Ingrezza fails study in pedriatric Tourette's patients
Tuesday, 23 May 2017 04:01pm EDT 

May 23 (Reuters) - Neurocrine Biosciences Inc :Neurocrine announces phase ii results of vmat2 inhibitor ingrezza® for treatment of tourette syndrome.Neurocrine biosciences inc- study did not meet its primary endpoint.Neurocrine biosciences inc- there were a total of four discontinuations due to adverse events, two in each of placebo and ingrezza arms in study.Neurocrine biosciences inc- company is also conducting an open-label, fixed-dose study of ingrezza in up to 180 subjects with tourette syndrome.  Full Article

Neurocrine and Bial reports exclusive North American licensing agreement for opicapone
Thursday, 9 Feb 2017 04:01pm EST 

Neurocrine Biosciences Inc : Neurocrine and Bial announce exclusive North American licensing agreement for opicapone . Neurocrine will be responsible for development and commercialization of opicapone in united states and canada . Will make upfront payment of $30 million and will fund all development activities necessary for U.S. FDA approval . Will pay Bial a percentage of net sales in exchange for manufacture and supply of opicapone drug product . Neurocrine Biosciences - upon completion of technology transfer from Bial, neurocrine intends to meet with fda to discuss potential NDA submission .Neurocrine Biosciences - Bial eligible to receive additional milestone payments of about $115 million from neurocrine for achievement of certain milestones.  Full Article

Neurocrine says INGREZZA NDA for treatment of tardive dyskinesia has been accepted for priority review by U.S. FDA
Tuesday, 11 Oct 2016 06:55am EDT 

Neurocrine Biosciences Inc : Neurocrine announces INGREZZA™ (valbenazine) new drug application for the treatment of tardive dyskinesia has been accepted for priority review by U.S. FDA .Neurocrine Biosciences Inc- INGREZZA application has been given a prescription drug user fee act (PDUFA) target action date of April 11, 2017.  Full Article

Neurocrine announces FDA conditional acceptance of Ingrezza
Wednesday, 31 Aug 2016 04:02pm EDT 

Neurocrine Biosciences Inc : Neurocrine announces FDA conditional acceptance of proprietary name Ingrezza™ for VMAT2 inhibitor valbenazine .Expects to receive notification of acceptance of NDA filing, as well as timeframe for NDA review from FDA in October 2016.  Full Article

Neurocrine submits NDA for Valbenazine
Monday, 29 Aug 2016 04:02pm EDT 

Neurocrine Biosciences Inc : Submits new drug application for Valbenazine for treatment of tardive dyskinesia .Expects to receive notification of acceptance of NDA, as well as timeframe for NDA review from FDA in october 2016..  Full Article

Neurocrine Biosciences Q2 loss per share $0.46
Wednesday, 3 Aug 2016 04:02pm EDT 

Neurocrine Biosciences Inc : Neurocrine biosciences reports second quarter 2016 results . Q2 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S .Q2 loss per share $0.46.  Full Article

Neurocrine Biosciences Inc announces positive results from phase III kinect 3 study of nbi-98854 in tardive dyskinesia
Thursday, 8 Oct 2015 06:30am EDT 

Neurocrine Biosciences Inc:Announces positive results from phase III kinect 3 study of nbi-98854 in tardive dyskinesia.Says study meets primary endpoint, submission of new drug application planned for 2016.Nbi-98854 showed statistically significant reduction in tardive dyskinesia during six weeks of placebo-controlled treatment.Says during the six-week placebo-controlled treatment period nbi-98854 was generally well tolerated.Clinical hematology, chemistry and ecg monitoring indicated no emergent safety signals.A separate 1-year open-label safety study of nbi-98854 been initiated to support the 2016 filing of nda in tardive dyskinesia.  Full Article

BRIEF-Perceptive Advisors reports 5.3 pct passive stake in Neurocrine Biosciences

* Perceptive Advisors LLC reports 5.3 percent passive stake in Neurocrine Biosciences Inc as of September 6, 2017 - SEC filing‍​ Source: (http://bit.ly/2wOUVQY) Further company coverage: